# Efficacy of Nirogacestat in Patients With Poor Prognostic Factors for Desmoid Tumors: Analyses From the Randomized Phase 3 DeFi Study

Ana B. Oton, MD<sup>7</sup>; Bernd Kasper, MD, PhD<sup>8</sup>

<sup>1</sup>Policlinico Universitario Campus Bio-Medico, Rome, Italy; <sup>2</sup>Stanford University, Stanford, CA, USA; <sup>3</sup>University, Stanford University, Stanford, CA, USA; <sup>3</sup>University, Stanford, Stanford, CA, USA; <sup>3</sup>University, Stanford, Stanford Duke University, Durham, NC, USA; <sup>6</sup>Washington University, Saint Louis, MO, USA; <sup>8</sup>University of Heidelberg, Mannheim University Medical Center, Mannheim, Germany

- symptom burden on patients, including pain and functional limitation<sup>1,2</sup>
- systemic treatment<sup>3,4</sup>
- key secondary endpoints of:

- for DT<sup>6-13</sup>



Accessed April 25, 2024.

- Presence of pain at baseline as determined by an average pain intensity (API) score of >0 on the Brief Pain Inventory–Short Form (BPI-SF)<sup>11,12</sup>

## Bruno Vincenzi, MD, PhD<sup>1</sup>; Nam Quoc Bui, MD<sup>2</sup>; Palma Dileo, MD<sup>3</sup>; Noah Federman, MD<sup>4</sup>; Richard F. Riedel, MD<sup>5</sup>; Brian A. Van Tine, MD, PhD<sup>6</sup>; Vincent Amoruccio, PhD<sup>7</sup>; Allison Lim, PharmD<sup>7</sup>;

9. Dômont J, et al. Br J Cancer. 2010;102(6):1032-1036. 15. Sørensen A, et al. *Acta Orthop Scand.* 2002;73(2):213-219. approved-drugs/fda-approves-nirogacestat-desmoid-tumors. Revised November 28, 2023. 10. Timbergen MJM, et al. *Ann Surg*. 2021;273(6):1094-1101. 16. Lazar AJF, et al. *Am J Pathol*. 2008;173(5):1518-1527.

Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from ASCO® or the author of this poster.



company (Chicago, IL), and was funded by SpringWorks Therapeutics, Inc.